Categories
Change Password!
Reset Password!
Dual diabetes therapies show diverging strengths as SGLT2 inhibitors lead in liver enzyme improvement, while GLP-1 receptor agonists dominate weight and glucose control in NAFLD patients.
Non-alcoholic fatty liver disease (NAFLD) is increasingly seen alongside type 2 diabetes mellitus (T2DM), forming a high-risk metabolic duo that strains both liver function and systemic health. Modern antidiabetic drugs are no longer limited to glucose control. They now influence weight, cardiovascular risk, and even liver biology. Among these, sodium–glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as dual-purpose therapies with distinct physiological impacts.
The study aimed to evaluate and compare how effectively these two drug classes improved liver function, blood sugar levels, and metabolic parameters in patients living with both conditions. Researchers carried out a structured systematic review and meta-analysis by pooling data from multiple clinical studies and real-world observations. Patient outcomes under SGLT2i and GLP-1RAs were systematically compared. Key indicators included liver enzyme levels, glycemic markers, and lipid-related outcomes, allowing a head-to-head evaluation of therapeutic performance. Both therapies delivered measurable benefits, but in different lanes.
A broader pattern also emerged:
The analysis revealed a clear therapeutic contrast rather than a competition. SGLT2i acted as liver-focused protectors, while GLP-1 RAs functioned as metabolic optimizers. This divergence suggested that treatment decisions should not follow a one-size-fits-all approach. Instead, therapy selection should be strategically matched to the patient’s dominant clinical need, whether that is restoring liver health or aggressively managing weight and glycemic balance.
Current Hepatology Reports
Efficacy of SGLT2 Inhibitors Versus GLP-1 Receptor Agonists in Type 2 Diabetes Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Mohamed Elnaggar et al.
Comments (0)